[{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"INV-101","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Forbion"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"INV-101","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INV-101","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INV-202","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INV-202","moa":"CB1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet\n","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Series C Financing","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ New Enterprise Associates","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ New Enterprise Associates"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"INV-202","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":1.0800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Novo Nordisk"}]

Find Clinical Drug Pipeline Developments & Deals by Inversago Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the acquisition, Inversago will further strengthen Nordisk's clinical pipeline in obesity, diabetes and other metabolic diseases by including its lead development asset INV-202, an oral CB1 inverse agonist, currently in a phase 2 trial for diabet...

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : $1,075.0 million

                          August 10, 2023

                          Lead Product(s) : INV-202

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Novo Nordisk

                          Deal Size : $1,075.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease.

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 29, 2022

                          Lead Product(s) : INV-202

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Proceeds from financing will be used to move lead program, INV-202, into a Phase 2 in Diabetic Kidney Disease in Q4 2022. Additionally, the funds will accelerate other programs currently in pre-clinical development, while establishing its leadership in C...

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 17, 2022

                          Lead Product(s) : INV-202

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : New Enterprise Associates

                          Deal Size : $95.0 million

                          Deal Type : Series C Financing

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : INV-202 showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversag...

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 15, 2022

                          Lead Product(s) : INV-202

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 19, 2022

                          Lead Product(s) : INV-202

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : INV-202, first-in-class, peripheral CB1 inhibitor, demonstrated efficacy in addressing multiple pathways involved in renal injury also have shown clinical improvements in lipids, weight loss and glucose.

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 15, 2022

                          Lead Product(s) : INV-202

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome, non-alcoholic steatohepatitis, type 1 diabetes, diabetic nephropathy and chronic kidney disea...

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 07, 2021

                          Lead Product(s) : INV-202

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : As a new generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi syndrome (PWS), NASH, type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among oth...

                          Brand Name : INV-202

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 07, 2021

                          Lead Product(s) : INV-202

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and non-alcoholic steatohepatitis (NASH).

                          Brand Name : INV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 07, 2021

                          Lead Product(s) : INV-101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Inversago will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose le...

                          Brand Name : INV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 29, 2020

                          Lead Product(s) : INV-101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank